Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda, Others Look To Overseas Growth To Offset Sluggish Japan Market

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical and fellow Japanese drug makers share a need to look abroad for ways to increase business in a shrinking domestic market. That need was behind Takeda's largest-ever acquisition bid by a Japanese drug maker for a foreign firm, the $8.8 billion offer for the U.S. biotech Millennium Pharmaceuticals. Takeda has a weak business structure in the U.S. and Europe when compared with foreign competitors and needed an acquisition. The domestic pharmaceutical market is considered sluggish despite 4.6 percent growth last year. (Click here for more - a subscription may be required

You may also be interested in...



Japan’s Pharmas Need R&D Reform: Tokyo Conference

TOKYO - The pharmaceutical market is rapidly increasing in complexity and pharmaceutical companies need to strengthen their 'mekiki ryoku' - translated 'eye for good judgment' in Japanese - said Ryoichi Inoue of Pharma Marketing Consultant, who is a former marketing executive at Roche in Japan

Coronavirus Notebook: UK To Run Vaccine Challenge Studies, CEPI Expands Manufacturing Network

Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.

Decision On Covid-19 TRIPS Waiver Postponed

WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel